The Profound Impact of Olfactory Dysfunction in CRSwNP

Loss of smell, medically termed anosmia or hyposmia, is one of the most distressing symptoms experienced by individuals with CRSwNP. This condition, characterized by chronic inflammation of the nasal passages and sinuses accompanied by the growth of nasal polyps, not only obstructs airflow but also triggers inflammatory processes within the olfactory epithelium, the specialized tissue responsible for detecting odors. The damage to this delicate system can lead to a significant reduction or complete loss of the ability to smell, which has far-reaching consequences. Beyond the diminished pleasure derived from food and aromas, the inability to smell can lead to social isolation, as shared experiences involving scents become inaccessible. Furthermore, it poses serious safety risks, preventing individuals from detecting hazardous substances like gas leaks, spoiled food, or smoke from fires.

Tezepelumab: A New Frontier in Targeting Type 2 Inflammation

Tezepelumab represents a significant advancement in the treatment of CRSwNP due to its unique mechanism of action. The drug targets thymic stromal lymphopoietin (TSLP), a key upstream cytokine that plays a central role in driving Type 2 inflammation. This inflammatory pathway is a well-established contributor to the pathogenesis of CRSwNP and is implicated in the olfactory dysfunction associated with the disease. By blocking TSLP, tezepelumab aims to disrupt the inflammatory cascade at its source, thereby alleviating the underlying pathology that leads to nasal polyps and impaired smell. This approach offers a distinct advantage over therapies that target downstream inflammatory mediators.

The WAYPOINT Trial: Design and Methodology

The robustness of the WAYPOINT trial’s findings stems from its rigorous Phase 3, multicenter, randomized, double-blind, placebo-controlled design. This gold-standard methodology ensures that the observed effects are attributable to the treatment and not to chance or patient expectation. The trial enrolled adults diagnosed with uncontrolled CRSwNP who were then randomly assigned in a one-to-one ratio to receive either tezepelumab at a dose of 210 mg or a placebo. The administration was subcutaneous, occurring every four weeks for a duration of 52 weeks, allowing for the assessment of both early and long-term efficacy.

The study meticulously evaluated multiple olfactory outcomes to provide a comprehensive picture of tezepelumab’s impact. These included:

  • Nasal Polyposis Symptom Diary (NPSD) loss-of-smell item: This patient-reported outcome measure captured daily fluctuations in the severity of smell loss, providing granular data on the onset and progression of symptom improvement.
  • University of Pennsylvania Smell Identification Test (UPSIT): A widely recognized psychophysical test that assesses a patient’s ability to identify common odors, serving as an objective measure of olfactory function.
  • Sino-Nasal Outcome Test (SNOT-22) loss-of-smell/taste item: Another validated patient-reported outcome that evaluates the impact of sinonasal disease on the sense of smell and taste, contributing to the overall assessment of quality of life.
  • UPSIT-defined anosmia prevalence: This specific metric focused on the proportion of patients who met the criteria for complete loss of smell (anosmia) based on their UPSIT scores, providing a clear indicator of the drug’s ability to reverse severe olfactory impairment.

The international multicenter nature of the trial ensured that the results were generalizable across diverse patient populations and healthcare settings.

Key Findings: Early Onset and Sustained Restoration of Smell

The analysis of the WAYPOINT trial data involved 408 patients, with 203 receiving tezepelumab and 205 receiving placebo. Baseline olfactory function was severely compromised in both groups, underscoring the significant burden of the disease. Mean NPSD loss-of-smell scores were 2.9, mean UPSIT scores were approximately 13.1 for tezepelumab and 11.9 for placebo, and mean SNOT-22 smell/taste item scores were 4.7 across both arms.

The results revealed a compelling picture of tezepelumab’s efficacy:

  • Rapid Onset of Improvement: Crucially, improvements in daily NPSD loss-of-smell scores were observed with tezepelumab compared to placebo as early as day seven of treatment. This rapid onset of benefit is particularly encouraging for patients experiencing significant distress from their olfactory dysfunction. The least-squares mean difference was -0.08, with a nominal P-value of less than 0.01, indicating a statistically significant and clinically meaningful early improvement.

  • Sustained and Significant Gains: By week four of treatment, tezepelumab demonstrated significantly greater improvements than placebo across all primary olfactory endpoints. The biweekly NPSD loss-of-smell score showed a difference of -0.36, the UPSIT score improved by 6.03 points, and the SNOT-22 smell/taste item score saw a reduction of -1.01, signifying less impairment.

  • Long-Term Efficacy Through 52 Weeks: The therapeutic benefits of tezepelumab were not transient. The improvements observed at week four were largely maintained throughout the 52-week treatment period. At the study’s conclusion, treatment differences remained substantial: -1.01 for NPSD, an impressive 9.50 for UPSIT, and -1.90 for SNOT-22 smell/taste score. All reported P-values for these long-term endpoints were nominal, suggesting statistical significance.

  • Marked Reduction in Anosmia: Perhaps one of the most impactful findings was the significant reduction in the prevalence of anosmia. Among patients with complete UPSIT data, the proportion experiencing anosmia was drastically lower in the tezepelumab group compared to placebo at both week four (43.0% vs. 80.3%) and week 52 (31.5% vs. 75.8%). Furthermore, the study reported an increase in the percentage of patients achieving normosmia (normal sense of smell) by week 52. In the tezepelumab group, normosmia increased from 0% at baseline to 10.7%, a notable achievement compared to the 2.3% observed in the placebo group.

Subgroup Analysis and Generalizability

The benefits of tezepelumab on smell were found to be consistent across various prespecified subgroups. This included analyses based on sex, prior nasal polyp surgery, duration of the disease, geographic region, and the presence of asthma or aspirin-exacerbated respiratory disease (AERD), as well as allergic rhinitis. This broad applicability suggests that tezepelumab may be a valuable treatment option for a wide spectrum of patients with CRSwNP experiencing olfactory dysfunction.

Limitations and Future Directions

While the WAYPOINT trial provides compelling evidence, the authors acknowledge certain limitations. Some analyses were conducted post hoc, meaning they were not pre-specified in the original trial protocol. Additionally, nominal testing was employed for many endpoints, which means the P-values should be interpreted with caution as they do not account for multiple comparisons. The reliance on the UPSIT, which primarily assesses odor identification, is also noted as a limitation, as it does not fully capture all aspects of olfactory function, such as olfactory threshold (the minimum concentration of an odor that can be detected) or olfactory discrimination (the ability to distinguish between different odors). Future research could explore the impact of tezepelumab on these specific olfactory parameters.

Expert Commentary and Broader Implications

Dr. Ashoke Khanwalkar, MD, provided expert commentary on the significance of these findings. He emphasized that loss of olfaction is a particularly distressing symptom for CRSwNP patients, arising from both physical obstruction by polyps and underlying epithelial inflammation. He noted that prior to the approval of tezepelumab for CRSwNP, dupilumab had emerged as a leading therapy for improving olfaction, often rivaling the benefits seen with surgical interventions.

Dr. Khanwalkar highlighted tezepelumab’s unique mechanism of targeting TSLP and stated that the WAYPOINT trial’s findings solidify its role as another valuable option in the therapeutic arsenal for managing this severe inflammatory disease. The ability of tezepelumab to significantly improve olfaction offers patients a renewed sense of well-being and a better quality of life.

The implications of the WAYPOINT study are substantial for the management of CRSwNP. By demonstrating early and sustained improvements in smell, tezepelumab offers a promising non-surgical avenue for addressing a symptom that profoundly impacts daily living. This could lead to a shift in treatment paradigms, with increased consideration for biologic therapies like tezepelumab for patients whose quality of life is severely compromised by olfactory dysfunction, even in the absence of severe nasal obstruction. The drug’s efficacy across diverse patient subgroups further strengthens its potential as a widely applicable treatment. As the understanding of Type 2 inflammation in CRSwNP deepens, targeted therapies like tezepelumab are poised to revolutionize patient care, offering hope for the restoration of vital sensory functions and an overall improvement in well-being.

The citation for the study is: Mullol J, et al. Early and sustained improvements in sense of smell with tezepelumab treatment in patients with chronic rhinosinusitis with nasal polyps (WAYPOINT). Int Forum Allergy Rhinol. 2026;16:484-494. doi:10.1002/alr.70090.